An advisory panel to the

Food and Drug Administration

recommended that

AstraZeneca's

(AZN) - Get Report

heartburn drug Prilosec be approved for sale over the counter.

The recommendation will go to the FDA, which usually follows the advice of its panels, but the agency has no obligation to do so.

Procter & Gamble

(PG) - Get Report

owns the rights to distribute the nonprescription formulation of Prilosec and asked the FDA to approve the drug for over-the-counter sales.

Shares of AstraZeneca ended Friday up 1.6% to $40.35, while P&G was unchanged at $93.85.